BRAK LABS Peptide research, plainly written

safety record

Acetyl octapeptide-3: what has been measured about safety

The safety record for acetyl octapeptide-3, read as a record: what two searches of the published record returned, whose assessment the one safety conclusion in this family belongs to, and what the two published studies can attribute.

Last Reviewed Editorial policy Methodology

The safety record for acetyl octapeptide-3 is a record of two searches and two studies, and the useful thing this page can do is say precisely what each of the four covers. A registry sweep on 23 August 2026 across the INCI name, the alternative octapeptide name and the trade name returned no registered study at any phase, in any country [10]. A PubMed search for the INCI name returns two records, and the count was unchanged between searches three weeks apart [9].

Both of those published studies are evaluations of dissolving microneedle patches carrying four or five active ingredients at once, and both report that their products were tolerated without adverse effects over their study periods, at 28 days and 12 weeks [1] [2]. Those observations belong to the finished patches rather than to this peptide, and neither study is built in a way that could attribute anything to one ingredient of five.

The record that a reader is most likely to be shown instead belongs to the six amino acid peptide this one extends. That molecule has a 2025 industry safety assessment with a concentration bound attached to it, and it has an FDA measurement of how far it travels through human skin [8] [5]. Both are about a different molecule, and this page says so each time rather than inheriting them.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Every sentence below reports what a named source measured or searched, in what system, and what it found. Where a result belongs to a different molecule, the page says which molecule in the same sentence rather than in a footnote.

This page publishes no dose, no schedule, no route instruction and no list of people who should avoid anything. A list of who should not use a compound is a directions-for-use document, and it only makes sense if the reader is going to use the thing. What replaces it is a description of the compound and its record, written about the molecule rather than about the reader.

One naming point is worth fixing before the first section, because it causes real confusion. The trailing 3 in this ingredient's INCI name belongs to the octapeptide series and is unrelated to the 3 in the former name of the peptide it extends. And the abbreviation resembles SNAP-25, which is a human protein inside the complex a nerve ending assembles. Those are three different things.

What has been measured

What the two searches returned, and what a search can establish

A registry sweep run through the ClinicalTrials.gov v2 API on 23 August 2026, covering acetyl octapeptide-3, acetyl octapeptide-8 and the trade name, returned no record at any phase, in any country, for any purpose [10]. A PubMed search for the INCI name on the same date returned two records, repeating a search first run on 2 August 2026 that returned the same two [9].

No published safety assessment of this ingredient was among them. That is a statement about what two searches returned rather than proof that no assessment exists anywhere, and this page states it as the first of those two things. Both searches are recorded with their terms and their dates so anyone can repeat them.

What follows from an empty search is narrower than it looks in either direction. It does not mean the ingredient was assessed and found wanting. It means nothing was found that would let anyone describe what it does, which is the position the rest of this page works from.

The two published studies, and what they can attribute

Both published records naming this ingredient are evaluations of dissolving microneedle patches. The first is a 24-subject evaluation of a patch carrying hyaluronic acid, this peptide, an ascorbic acid derivative and a lysophosphatidic acid salt, compared against a hyaluronic-acid-only patch on the other eye, so the comparator differs by three ingredients [1]. The second is a 12-week study of a patch carrying five actives with no comparator arm at all [2].

Both report that their products were tolerated without adverse effects over their study periods, at 28 days and 12 weeks [1] [2]. Read that as what it is: an observation about two finished patches, each carrying four or five active ingredients on a hyaluronic acid backbone, over weeks. Nothing in either is attributable to this peptide, in either direction, because neither design isolates it.

The delivery method matters as much as the mixture. A microneedle patch punctures the outer layer of skin, which is the barrier the whole delivery question for this class of ingredient concerns. An exposure that bypasses the barrier is a different exposure from a cream that has to cross it, and it is the larger of the two rather than a weaker version. [Anecdote] [1] [2]

The one safety assessment in this family, and whose molecule it covers

The six amino acid peptide this ingredient extends has a published safety assessment. The Expert Panel for Cosmetic Ingredient Safety published it in 2025, reaching a conclusion of safety in cosmetics in the present practices of use bounded at concentrations up to 0.005 per cent, and stating that available data are insufficient to reach that conclusion above it [8].

That assessment is of a different molecule. Two extra amino acids make a different chemical entity with different size, different behaviour and a different submitted data package, and the sole reason this ingredient is preferred in the market is precisely that the difference is supposed to matter. A reader cannot be asked to accept the difference as an advantage and then accept the parent's assessment as this one's record.

This site does not describe any compound as safe. Nothing in this section is a statement about whether this ingredient is, and the assessment quoted here is a named panel's dated conclusion about something else.

The arrival measurement, and which molecule it was made on

The most load-bearing measurement in this family is about delivery, and it was made on the shorter peptide. A US Food and Drug Administration laboratory applied that molecule at 10 per cent to human cadaver skin for 24 hours and measured every layer, finding 0.22 per cent of the applied dose in the outer layer, 0.01 per cent in the epidermis, and none in the dermis or the fluid beneath the skin [5]. A 2025 review of that ingredient concludes that low skin penetration limits its bioavailability and that whether it reaches neuromuscular junctions remains uncertain [3].

Nothing equivalent has been measured for this ingredient. What can be said is a property rather than a result: an eight amino acid peptide is larger than a six amino acid one, and molecular size and water-loving character are the two properties the class reviews name as making these peptides difficult to deliver across a lipid barrier.

That points somewhere specific for a safety question rather than only for an efficacy one. The exposure this ingredient produces from a cream has never been measured, in either direction, and the nearest measurement belongs to a smaller molecule that put nothing below the epidermis.

What has not been characterised

Set out plainly, so the shape of the gap is visible rather than implied. No study of any design has tested this ingredient on its own, so nothing is published on what it does to cells, what it does to skin, how much of an applied dose arrives anywhere, or what repeated use produces. No registered study exists under any of its names [10], and the two published records both carry it inside a mixture [1] [2].

No published safety assessment of this ingredient was found in a PubMed search [9]. That is a search result rather than a fact about the world, and the distinction is the difference between saying what was looked for and claiming what exists.

And nothing published ranks this ingredient against the peptide it extends, on any measure, in any species. Every comparative statement in circulation traces to supplier material that has not been published, which means a reader has nothing to check and neither does this page.

Our takeThis page is short because the record is, and the honest version of that is worth more than a borrowed one. Two searches returned two studies, both of mixtures delivered through a barrier-puncturing patch, and neither can attribute anything to this ingredient. The only safety assessment in the family covers the shorter peptide, and the only arrival measurement was made on it too. A market that sells this ingredient as the stronger version cannot then hand a reader the weaker version's file as its evidence.

Talk to a licensed clinician about anything concerning your health.

Frequently asked questions

Is acetyl octapeptide-3 safe?

This site takes no position on that for any compound, and here there is nothing on the record that could inform one. A PubMed search on 23 August 2026 found no published safety assessment of this ingredient, and a registry sweep found no registered study under any of its names [9] [10]. The 2025 assessment that exists in this family covers the six amino acid peptide this one extends, which is a different molecule [8].

Were any side effects reported in the published studies?

Both microneedle patch studies report that their products were tolerated without adverse effects over their study periods, at 28 days and 12 weeks [1] [2]. Those are observations about finished patches carrying four or five active ingredients each, and nothing in either is attributable to this peptide in either direction.

Does the assessment of acetyl hexapeptide-8 cover this ingredient?

No. It is an assessment of a different molecule, published in 2025 with a concentration bound attached to it [8]. Two extra amino acids make a different chemical entity, and the entire reason this ingredient is sold as the stronger one is that the difference is supposed to matter. The parent's record is set out on its own safety page, linked at the foot of this one.

Does it get into the bloodstream?

Nothing published measures that for this ingredient. The nearest measurement was made on the shorter peptide it extends: an FDA laboratory applied that molecule at 10 per cent to human cadaver skin for 24 hours and detected none of it in the dermis or the fluid beneath [5]. An eight amino acid peptide is larger, and size is one of the two properties the class reviews name as making these molecules hard to deliver [3].

Do the microneedle patch studies say anything about a cream?

They answer a different question. A microneedle patch punctures the outer layer of skin, which is the barrier every delivery question about this class concerns, so a result obtained through it describes a larger exposure rather than the same one [1] [2].

What would change what this page says?

A study testing this ingredient on its own, in any design, would, and it would be the first [9] [10]. So would a published safety assessment of it, since none was found. And so would a measurement of how much of an applied dose reaches each layer of skin, which exists for the shorter peptide and has never been made for this one.

References

  1. Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. PMID 39082657 DOI 10.5021/ad.23.136
  2. Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. PMID 31134751 DOI 10.1111/jocd.13009
  3. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185 DOI 10.3390/ijms26125722
  4. Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022. PMID 35302659 DOI 10.1111/ics.12770
  5. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. PMID 24754410 DOI 10.3109/15569527.2014.894521
  6. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002. PMID 18498523 DOI 10.1046/j.1467-2494.2002.00153.x
  7. Skibska A, Perlikowska R. Signal Peptides - Promising Ingredients in Cosmetics. Curr Protein Pept Sci. 2021. PMID 34382523 DOI 10.2174/1389203722666210812121129
  8. Johnson W Jr, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Marks JG Jr, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Fiume M, Heldreth B. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025. PMID 40673537 DOI 10.1177/10915818251340391
  9. US National Library of Medicine. PubMed, searched for the term acetyl octapeptide-3 on 23 August 2026, repeating a search first run on 2 August 2026. Both returned the same two records, PMID 39082657 and PMID 31134751, each a study of a multi-ingredient microneedle patch. No record testing the peptide on its own was returned. Searches for acetyl octapeptide and for a Cosmetic Ingredient Review safety assessment of the octapeptide returned no record of either. PubMed. 2026. Source document
  10. ClinicalTrials.gov. Registry sweep for acetyl octapeptide-3, acetyl octapeptide-8 and SNAP-8 peptide, run through the v2 API on 23 August 2026. Each of the three queries returned no record, at any phase, in any country. The same sweep returned six records for acetyl hexapeptide-8, which are covered on that compound's page. ClinicalTrials.gov. 2026. ClinicalTrials.gov
  11. United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
  12. Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 23 August 2026. United States Code. 2026. Source document
  13. Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 23 August 2026. Electronic Code of Federal Regulations. 2026. Source document